535.67
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$529.05
Aprire:
$529.29
Volume 24 ore:
420.32K
Relative Volume:
0.93
Capitalizzazione di mercato:
$22.74B
Reddito:
$3.17B
Utile/perdita netta:
$1.29B
Rapporto P/E:
19.77
EPS:
27.0947
Flusso di cassa netto:
$1.01B
1 W Prestazione:
-2.08%
1M Prestazione:
-2.87%
6M Prestazione:
+15.22%
1 anno Prestazione:
+80.16%
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
UTHR
United Therapeutics Corp
|
535.67 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.15 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
10.10 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.03 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
76.56 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Underweight |
| 2025-09-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
United Therapeutics Corp (UTHR) - MSN
United Therapeutics CEO Rothblatt sells $5.04 million in company shares - Investing.com
United Therapeutics CEO Rothblatt sells $5.04m in UTHR shares By Investing.com - Investing.com South Africa
United Therapeutics CEO Rothblatt sells $5.04m in UTHR shares - Investing.com
Form 4 United Therapeutics Corporation For: 16 July By Investing.com - Investing.com Canada
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics CEO Rothblatt sells $5.09m in company stock - Investing.com
Form 4 United Therapeutics Corporation For: 14 July By Investing.com - Investing.com India
United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise - Stock Titan
Form 4 United Therapeutics Corporation For: 13 July By Investing.com - Investing.com South Africa
[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity - Stock Titan
United Therapeutics director Jan Malcolm sells $178,941 in stock - Investing.com UK
United Therapeutics director Jan Malcolm sells $178,941 in stock By Investing.com - Investing.com Australia
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
United Therapeutics: CEO's Multi-Million Dollar Sales Signal Caution Amidst Bullish Consensus - Kavout | AI
Form 4 United Therapeutics Corporation For: 10 July By Investing.com - Investing.com South Africa
UTHR Stock Quote Price and Forecast - CNN
United Therapeutics CEO Martine Rothblatt sells $5.2m shares - Investing.com UK
United Therapeutics CEO Martine Rothblatt sells $5.2m shares By Investing.com - Investing.com Australia
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.25m By Investing.com - Investing.com Australia
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.25m - Investing.com
Form 4 United Therapeutics Corporation For: 9 July By Investing.com - Investing.com Canada
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know - TradingView
United Therapeutics CEO Martine Rothblatt sells $5.3m company stock - Investing.com
Form 4 United Therapeutics Corporation For: 8 July By Investing.com - Investing.com South Africa
United Therapeutics CEO Martine Rothblatt sells $5.3m company stock By Investing.com - Investing.com Nigeria
Is United Therapeutics Corporation (UTHR) Stock a Long-Term Opportunity in Organ Transplant Innovation? - Insider Monkey
United Therapeutics expands immune therapy pipeline with Thymmune - BioBuzz
United Therapeutics focuses on pulmonary arterial hypertension. Nasdaq-listed biotech builds on its - Ad-hoc-news.de
United Therapeutics Corp (UTHR) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 88/100 - GuruFocus
United Therapeutics CEO Rothblatt sells $5.2m in company stock By Investing.com - Investing.com South Africa
Form 4 United Therapeutics Corporation For: 7 July By Investing.com - Investing.com Nigeria
United Therapeutics CEO Rothblatt sells $5.2m in company stock - Investing.com
United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy - Seeking Alpha
United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises (NASDAQ:RGC) - Seeking Alpha
RTP drugmaker strikes $300M deal for Massachusetts company - The Business Journals
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
United Therapeutics Corp Azioni (UTHR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 16 '26 |
Sale |
530.91 |
9,500 |
5,043,689 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 15 '26 |
Option Exercise |
135.42 |
7,782 |
1,053,838 |
332,225 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 15 '26 |
Option Exercise |
135.42 |
1,718 |
232,652 |
42,231 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 15 '26 |
Sale |
530.34 |
7,782 |
4,127,087 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jul 15 '26 |
Sale |
530.41 |
1,718 |
911,253 |
40,513 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jul 16 '26 |
Option Exercise |
146.03 |
8,300 |
1,212,049 |
53,472 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jul 16 '26 |
Sale |
533.69 |
8,300 |
4,429,638 |
45,172 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):